Royalty Pharma plc offers defensive biopharma growth, high returns, and portfolio diversification. Click to read the RPRX investment case now.
NEW YORK (AP) — NEW YORK (AP) — Royalty Pharma (RPRX) on Wednesday reported third-quarter earnings of $145 million.The New York-based company said it had profit of 26 cents per share.
Royalty Pharma invests in a portfolio of drugs, from blockbusters to those still in development.
Royalty Pharma kept printing upbeat headlines, with recurring royalty receipts rising and new late stage deals like cliramitug and rusfertide added to the portfolio, even as one quarterly net margin compressed from 5.6% to 2.7%. For Royalty Pharma shareholders, the return over the past year was 74.7%, including dividends. If you had been weighing the bullish growth story against debt, pricing pressure, and pipeline risk in October 2025, what made that trade off worth accepting? The useful...
Detailed price information for Royalty Pharma Plc Cl A (RPRX-Q) from The Globe and Mail including charting and trades.
Tipranks Press Release.
Royalty Pharma (NASDAQ:RPRX) has outperformed the market over the past 10 years by 26.07% on an annualized basis producing an average annual return of 39.61%. Currently, Royalty Pharma has a market capitalization of
Revolution Medicines' stock is up 330% in a year on drug development progress; you may want to spread your bets with Royalty Pharma instead.
Royalty Pharma has delivered a strong share price run in recent years, which naturally puts fresh attention on what investors are paying for its earnings today. With the stock now around US$58.52, the key issue is how that outcome lines up with the underlying profit engine of its royalty portfolio. Over the last 3 years, Royalty Pharma has returned about 136.3%, which increases the stakes on whether its current earnings base can carry that kind of share price progress. The recent US$7.5...
Blood Cancer United and Royalty Pharma today announced a $7.5 million donation from Royalty Pharma to support Blood Cancer United's Therapy Acceleration Program (TAP), a collaborative venture philanthropy initiative designed to accelerate the development of promising blood cancer therapies through strategic equity investments and hands-on collaboration with biotech companies.
Royalty Pharma plc (NASDAQ:RPRX) disclosed that pelacarsen failed the Phase 3 Lp(a)HORIZON cardiovascular-outcomes trial conducted by Novartis AG (NYSE:NVS). The randomized, double-blind study enrolled 8,323 patients with elevated lipoprotein(a), or Lp(a), and established cardiovascular disease. Pelacarsen lowered Lp(a), but the study did not meet its primary endpoint of reducing cardiovascular events compared with placebo in […]
Detailed price information for Abbvie Inc (ABBV-N) from The Globe and Mail including charting and trades.
NEW YORK, Sept. 09, 2026 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will participate in the following upcoming investor conferences during the month of September: Morgan Stanley 24th Annual Global Healthcare Conference on Monday, September 14, 2026 at 2:35 p.m. EDTBofA Global Research Global Healthcare Conference on Wednesday, September 23, 2026 at 11:45 a.m. BST The webcast will be accessible from Royalty Pharma’s “Events” page at https://www.royaltypharma.com
Royalty Pharma (RPRX) shares fell nearly 6% in Tuesday trading after Novartis' (NVS) experimental he
This is the newest page. Registered accounts read further back.